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Multidrug-resistant  Achromobacter xylosoxidans was
recovered from the sputum of a patient with cystic fibrosis.
The VEB-1 extended-spectrum β-lactamase was detected
on a class 1 integron. This first report of a VEB-1–produc-
ing isolate in this population requires further investigation to
determine its distribution.
A
chromobacter (formerly Alcaligenes) xylosoxidans is a
newly emerging microorganism isolated with
increased frequency from the lungs of patients with cystic
fibrosis (CF), but information about its clinical relevance
is limited (1). A. xylosoxidans is innately resistant to many
antimicrobial drugs (2), except piperacillin, piperacillin-
tazobactam, and imipenem, and moderately susceptible to
ceftazidime (45% of susceptible isolates), which is widely
used to treat infection due to Pseudomonas aeruginosa
(3,4). The mechanisms involved in cases of high-level
resistance to ceftazidime have not been described for A.
xylosoxidans. Possible mechanisms for ceftazidime resist-
ance among gram-negative bacilli are alterations in outer
membrane proteins, overproduction of cephalosporinase,
or production of an extended-spectrum β-lactamase
(ESBL). ESBLs are enzymes distributed worldwide (5)
that hydrolyze oxyimino-cephalosporins and monobac-
tams and are susceptible to β-lactamase inhibitors such as
clavulanic acid and tazobactam. We report on the isolation
from a CF patient of A. xylosoxidans that produced the
VEB-1 ESBL. This is the first report of ESBL production
in A. xylosoxidans and the first report of a VEB-1–produc-
ing isolate from a CF patient.
The Study
During the past 10 years in our 1,600-bed university
hospital, 37 CF patients had ≥1 respiratory tract specimen
that contained A. xylosoxidans. Preliminary pulsed-field
gel electrophoresis of these strains has failed to identify
shared isolates among the patients, but studies are ongoing.
In November 2003, A. xylosoxidans 476 (AX476) was iso-
lated from the sputum of a 17-year-old male CF patient.
This patient had good pulmonary function (forced expira-
tory volume 1 = 99% of predicted value), had never been
colonized or infected by P. aeruginosa, and therefore never
received ceftazidime. The strain was identified with the
Api 20NE system (bio-Mérieux, Marcy-l’Etoile, France),
and antimicrobial susceptibility testing was performed and
interpreted as recommended by the Clinical and
Laboratory Standards Institute (formerly NCCLS) (6).
The antibiogram, which was performed by a disk diffu-
sion method, showed AX476 to be highly resistant to cef-
tazidime, aminoglycosides, sulfonamides, trimethoprim,
and ciprofloxacin but fully susceptible to tetracyclines,
piperacillin/tazobactam, ticarcillin/clavulanic acid, and
imipenem. Because of an unusual synergy between ticar-
cillin and ticarcillin/clavulanic acid (Figure), we compared
the inhibition zones of third-generation cephalosporin
disks with and without clavulanic acid (BioRad, Marnes-
la-Coquette, France). The zones were 7 mm for cef-
tazidime and 19 mm for ceftazidime plus clavulanic acid
(Figure), which strongly indicated production of an ESBL.
Isoelectric focusing showed that AX476 produced a β-lac-
tamase with an isoelectric point of 7.4. A large plasmid of
≈200 kb (pJDB1) was easily transferred by conjugation to
Escherichia coli K-12 C600. The transconjugants, E. coli
(pJDB1) sorbitol-fermenting, which were selected on
MacConkey agar that contained 4 µg/mL of ceftazidime,
were resistant to sulfonamides and trimethoprim, had
reduced susceptibility to aminoglycosides, and harbored a
β-lactamase with an isoelectric point of 7.4. The resistance
phenotype of the isolate and the value of the isoelectric
point of the enzyme suggested the production of the ESBL
VEB-1 (7). 
The MICs for β-lactams for AX476 and its transconju-
gant, determined by Mueller-Hinton broth dilution
method, are shown in Table 1. By using blaVEB-1-specific
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Figure. A) Oval indicates area of synergy between ticarcillin (TIC)
and TIC plus clavulanic acid (CA). B) Arrows point to inhibition
zone around third-generation disks with and without CA. AMX,
amoxicillin; FEP, cefepime; CAZ, ceftazidime; CTX, cefotaxime;
CF, cefalotin.primers, a positive PCR result was obtained on total DNA
from AX476 and the transconjugants. All genetic analyses
of blaVEB-1 published so far have identified either its chro-
mosome (8) or its plasmid (9) location and mostly its inte-
gration within class 1 integrons of variable structure.
Integrons are potentially mobile genetic elements that
comprise conserved sequences that flank a variable region
and may contain inserted antimicrobial drug resistance
gene cassettes (10). The 5′-conserved segment includes the
gene intI1 that encodes an integrase, the cassette integra-
tion site attI1, and a promoter responsible for the expres-
sion of the genes located downstream within the variable
region. The 3′-conserved region contains either a qacE∆1
gene that encodes resistance to quaternary ammonium
compounds or a combination of 3 genes: qacE∆1,  sulI
(which encodes resistance to sulfonamides), and orf5 (an
open reading frame of unknown function). 
To search for the presence of such a class 1 integron in
AX476 and its transconjugant, we performed PCR on total
DNA of AX476 and E. coli (pJDB1) by using the primers
L1 and R1 specific for the detection of class 1 integrons
(11). We obtained a fragment of 2.3 kb in the clinical strain
and its transconjugant, which was sequenced on both
strands. By using a set of primers, we deduced the struc-
ture of this integron (Table 2). Three gene cassettes have
been identified. The first, dhfr (dihydrofolate reductase),
encoded a putative trimethoprim-resistance protein. This
dhfr was identical to that reported in Salmonella enterica
serovar Typhi (GenBank accession no. AL513383) and to
the dhfr gene cassette contained in a class 1 integron from
Klebsiella pneumoniae not yet published (GenBank acces-
sion no. AJ971342). The second cassette, blaVEB-1, encod-
ed the ESBLVEB-1 first described in E. coli (7). The third
and last gene cassette was aadB. It encoded an aminogly-
coside adenyltransferase that conferred resistance to
kanamycin, gentamicin, and tobramycin and was identical
to other sequenced aadB gene cassettes located on inte-
grons containing blaVEB-1 gene (7,8). VEB-1 has been
detected in Enterobacteriaceae and P. aeruginosa isolates
from Southeast Asia (9) but never in A. xylosoxidans. In
France, VEB-1–producing isolates of Acinetobacter bau-
mannii have been involved in several outbreaks of nosoco-
mial infection in intensive care units (12,13); however, we
have not yet detected a VEB-1–producing isolate in our
hospital.
Conclusions
This finding of a VEB-1–producing A. xylosoxidans
from a CF patient enhances the scant information available
to laboratorians and clinicians about ESBL production by
isolates from CF patients. A very recent study reports 3
ESBL-positive isolates of P. aeruginosa from CF patients
in New Delhi, but the ESBL has not been characterized
(14). Resistance to expanded-spectrum cephalosporins
mediated by ESBLs has never been described in A. xylosox-
idans. The detection of the ESBL production was difficult
in AX476; therefore, the frequency of A. xylosoxidans
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We recommend the use of  BioRad combination disks,
especially for isolates that are highly resistant to  cef-
tazidime and susceptible to piperacillin or when  synergy
exists between ticarcillin and ticarcillin plus clavulanic
acid. 
The origin of the strain remains unclear. Because A.
xylosoxidans is widely encountered in the environment,
acquisition of AX476 by our patient may have resulted
from poor adherence to handwashing, contamination of
respiratory therapy equipment (nebulizer), or contaminat-
ed water. We can exclude nosocomial acquisition because
our patient had never been hospitalized. 
The location of blaVEB-1 on an easily transferable plas-
mid might represent a clinical threat if spread among other
species widely encountered among CF patients, especially
P. aeruginosa. Such a transfer would create serious thera-
peutic problems. Therefore, to prevent person-to-person
transmission, our patient visits the physician on different
days than the other CF patients. If he needs to be hospital-
ized, our patient may not share a room with immunocom-
promised patients or with other CF patients anywhere in
the hospital, which is the recommendation for patients
with other multidrug-resistant pathogens (15). In conclu-
sion, this first finding of a VEB-1–producing A. xylosoxi-
dans from a CF patient emphasizes the need to study the
mechanism(s) of resistance to ceftazidime among a wide
collection of isolates originated from different centers. The
sequence of the class 1 integron reported in this paper has
been assigned GenBank accession no. DQ393569.
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